ReviewAging clinical and experimental research2024
Radiofrequency echographic multi spectrometry (REMS) in the diagnosis and management of osteoporosis: state of the art.
Review in Aging clinical and experimental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Fracture Risk Stratification by REMS: A 5 Years Prospective Longitudinal Multicentre Study.Calcified tissue international · 2026Observational
- Single-component imaging and ultrasound-based tools for the assessment of fracture risk.Nature reviews. Rheumatology · 2026Review
- Intraoperative mechanical characterization of vertebral bone quality during percutaneous kyphoplasty.Mechanobiology in medicine · 2026Article
- Femoral Skeletal Growth in Early Infancy Assessed by Radiofrequency Echographic Multi-Spectrometry.Journal of clinical ultrasound : JCU · 2026Article
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- Radiofrequency Echographic Multi-Spectrometry (REMS) for Bilateral Femoral Neck Assessment in Pregnant Women: A Cross-Sectional Study.Life (Basel, Switzerland) · 2026Article
- Early Identification of Low Bone Density Risk Using a Radiofrequency Echographic Multi Spectrometry-Based Prediction Model.Life (Basel, Switzerland) · 2026Article
- Combination of Biomarkers and Novel Diagnostic Tools in the Management of Osteoporosis in Chronic Kidney Disease: An Update.Journal of clinical medicine · 2026Review
- Methodological Clarification and Analysis of Demographic and Anthropometric Determinants in the Calculation of REMS Bone Mineral Density.Calcified tissue international · 2026Article
- Demographic determinants of REMS-derived BMD and fragility score.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology.Aging clinical and experimental research · 2026Article
- Comparative longitudinal assessment of bone mineral density measured with radiofrequency echographic multi-spectrometry (REMS) and dual X-ray absorptiometry (DXA) in a cohort of peritoneal dialysis patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Letter comments on: Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Article
- Concordance between radiofrequency echographic multispectrometryand dual X-ray absorptiometry in diagnosing osteoporosis among postmenopausal women: a real-world study.Archives of osteoporosis · 2025Article
- Osteoporosis and Fracture Risk in Ovarian Cancer: Beyond the Oncologic Burden.Diagnostics (Basel, Switzerland) · 2025Review
- Utility of REMS-Derived Fragility Score and Trabecular Bone Score in Evaluating Bone Health in Type 2 Diabetes Mellitus.Diagnostics (Basel, Switzerland) · 2025Article
- Editorial: Is REMS-BMD Truly a Measured Parameter? A Call for Transparency and Technical Clarification.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Clinical application of radiofrequency echographic multi-spectrometry (REMS) for diagnosis and follow-up in several rare bone disorders: a case series.BMC medical imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Radiofrequency Echographic Multi Spectrometry (REMS) is a radiation-free, portable technology, which can be used for the assessment and monitoring of osteoporosis at the lumbar spine and femoral neck and may facilitate wider access to axial BMD measurement compared with standard dual-energy x-ray absorptiometry (DXA).There is a growing literature demonstrating a strong correlation between DXA and REMS measures of BMD and further work supporting 5-year prediction of fracture using the REMS Fragility Score, which provides a measure of bone quality (in addition to the quantitative measure of BMD).The non-ionising radiation emitted by REMS allows it to be used in previously underserved populations including pregnant women and children and may facilitate more frequent measurement of BMD.The portability of the device means that it can be deployed to measure BMD for frail patients at the bedside (avoiding the complications in transfer and positioning which can occur with DXA), in primary care, the emergency department, low-resource settings and even at home.The current evidence base supports the technology as a useful tool in the management of osteoporosis as an alternative to DXA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.